Special Issue "Radiolabelled Molecules for Brain Imaging with PET and SPECT"
Deadline for manuscript submissions: closed (5 January 2020).
Interests: radiotracer development for brain tumor imaging (glioblastoma, brain metastases); neuroimaging of the cholinergic system (nicotinic acetylcholine receptors, vesicular acetylcholine transporter); neuroimaging of second messenger systems (phosphodiesterases 2, 5, and 10); neuroimaging of neuromodulatory processes (sigma and cannabinoid receptors, adenosine signaling); blood–brain barrier transport of radiopharmaceuticals
Special Issues and Collections in MDPI journals
Special Issue in Molecules: Radiolabelled Molecules for Brain Imaging with PET and SPECT II
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging tools which are widely used in nuclear medicine for the diagnosis and treatment follow-up of many brain diseases, including neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, psychiatric syndromes, such as major depression and schizophrenia, or brain tumors, with glioblastoma multiforme as the most aggressive type of brain-derived cancers. The success of PET and SPECT imaging very much depends on the suitability of imaging probes, which are labeled with radionuclides of short half-lives. The delivery of those radiotracers to the brain and their subsequent quantification with PET and SPECT provides images of biochemical processes such as transport, metabolism, and neurotransmission on the molecular level. In addition to the diagnostic and therapeutic use as radiopharmaceuticals, in the field of nuclear medicine, they provide powerful tools for in vivo pharmacology during the process of preclinical drug development to identify new drug targets, to investigate the pathophysiology, to discover potential drug candidates, and to evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo. Furthermore, they allow molecular imaging studies in various small-animal models of disease, including genetically-engineered animals.
All researchers working in this very interdisciplinary field are cordially invited to contribute original research papers or reviews to this Special Issue of Molecules, which is related to the development and use of radiolabeled molecules for brain imaging.
Prof. Dr. Peter Brust
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Radiolabelled iodine
- Alzheimer´s disease
- Parkinson´s disease
- Brain cancer